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P orphyromonas gingivalis, a Gram-negative anaerobic bacterium, hasemerged as a leading candidate pathogen in the development of chronic
periodontitis (Socransky et al., 1998). This micro-organism possesses
multiple pathogenic factors such as lipopolysaccharides, capsular
polysaccharides, fimbriae, hemagglutinins, and proteases (Mayrand and
Holt, 1988). Among these, gingipains, a group of cysteine proteases, are
major weapons in its arsenal of attack on the periodontal region. Gingipains
consist of Arg-gingipains (RgpA and RgpB) and Lys-gingipain (Curtis et
al., 1999). They are believed to play a major role in the pathogenesis of
periodontitis, degrading a variety of host proteins. In this way, they
dysregulate the host defense mechanisms, resulting in tissue destruction and
alveolar bone resorption (Grenier et al., 2003; Houle et al., 2003; Imamura,
2003; Goulet et al., 2004).
Immunization studies with P. gingivalis in animal models have
produced encouraging results which suggest that vaccine-elevated IgG
levels can protect against periodontal disease (Gibson and Genco, 2001;
Rajapakse et al., 2002; Gonzalez et al., 2003). Mucosal immunity, in which
sIgA is a key factor, is the first line of defense against pathogens, working to
prevent systemic or local infection. We previously reported that
immunization of mice with rgpA DNA vaccine elicited high levels of
specific IgGs against P. gingivalis (Yonezawa et al., 2001). In this study, we
evaluated the effect of intranasal (i.n.) immunization with a DNA vaccine.
MATERIALS & METHODS
Vaccination with Gene Gun and HVJ Envelope Vector
Approval to conduct this study was obtained from the Animal Use Committee of
Tokyo Dental College. A six-week-old female BALB/c mouse (Sankyo
Laboratories Service Co. Inc,, Tokyo, Japan) was used for each vaccination.
Immunization with the rgpA DNA vaccine was performed as described
previously (Yonezawa et al., 2001). Briefly, pVax1 (Invitrogen, Carlsbad, CA,
USA) harboring the whole rgpA open reading frame from P. gingivalis
ATCC33277 was used as the rgpA DNA vaccine. Gold particles (1.6-m) were
coated with the vaccine according to the manufacturer's instructions. A Helios
Gene Gun (Bio-Rad Laboratories, Hercules, CA, USA) was used to give the
mice a total of 2.5 g DNA via the skin of the abdomen at wks 0, 1, 2, 3, 4, 5, 6,
and 7.
Intranasal immunization with the rgpA DNA vaccine was performed with
the hemagglutinating virus of Japan (HVJ) envelope vector kit (Ishihara-Sangyo
Kaisha Ltd., Osaka, Japan), according to the manufacturer's instructions. A 160-
L HVJ envelope vector suspension was centrifuged at 10,000 x g for 5 min.
The pellet was re-suspended in 10 L rgpA DNA vaccine (16 g/L) and 80
L bovine serum albumin (BSA) solution. After the addition of 2% Triton X-
100 (8 L), the mixture was centrifuged at 10,000 x g for 5 min. The pellet was
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finally re-suspended in 80 L BSA solution. The mice were
nasally immunized with rgpA-HVJ-E vector (20 g/10 L/mouse)
at wks 0, 1, 2, 3, 4, 5, 6, and 7. Vaccination for investigation of the
kinetics of the antibody response and evaluation of the protective
effect of the vaccination described below was performed
independently.
ELISA and Immunoblot
Serum and saliva samples were obtained from the mice on days 0,
7, 14, 21, 28, 35, 42, and 49. Anti-rgpA antibodies in the serum
and saliva were detected by enzyme-linked immunosorbent assay
(ELISA) as previously described (Yonezawa et al., 2001). A 20-
g sonic extract of P. gingivalis ATCC33277 was coated onto flat-
bottomed polystyrene microplates (Corning, Corning, NY, USA),
and the wells were blocked. Duplicate serial two-fold-diluted
samples were applied to the wells and incubated at 37°C for 60
min. After wells were washed, peroxidase-labeled goat antibody
against mouse IgG, IgG1, IgG2a, IgG2b, IgG3, or IgA (ICN
Biomedicals, Inc., Aurora, OH, USA) was applied. After
development, absorbance at 405 nm was measured with a
microplate reader (Bio-Rad Laboratories). The endpoint titer for
antigen-specific immunoglobulins was defined as the last dilution
giving an optical density at 405 nm of > 0.15. Specificity of
salivary sIgA was confirmed by immunoblot analysis, with each
recombinant fusion protein of the Rgp domain expressed by
pET32Xa/LIC (Novagen, Gibbstown, NJ, USA), as described
previously (Yonezawa et al., 2001). These consisted of the
histidine tag protein and each domain. The deduced molecular
masses of the histidine-tag (17388.5) of pET32Xa/LIC and
catalytic subunits, HGRP44 and HGRP 15-27, were 71258.3,
62058.8, and 78729.4, respectively.
P. gingivalis Challenge Studies
To evaluate the protective effect of the vaccination against P.
gingivalis, we infected the immunized mice with P. gingivalis as
described previously (Baker et al., 1994), with minor
modifications. The BALB/c mice were separated into 4 groups: a
non-immunized group (n = 10), a group immunized with the rgpA
DNA vaccine via the skin of the abdomen by a Gene Gun (n = 5), a
group immunized intranasally with rgpA-HVJ-E vector (n = 5),
and a group immunized with pVAX1 (Invitrogen, Carlsbad, CA,
USA) alone (n = 5). The serum IgG and salivary sIgA antibody
titers were evaluated at 4 to 6 wks as described above. When the
antibody titers of the mice immunized by Gene Gun and
intranasally with rgpA-HVJ-E vector reached a plateau, the mice
were challenged with P. gingivalis. Following immunization, the
mice were given 5 mg each of kanamycin and ampicillin by
gavage, once a day for 4 days. This was followed by a three-day
antibiotic-free period. They were then challenged with
approximately 1 x 109 CFUs of live P. gingivalis ATCC33277
suspended in 100 L of 2% carboxymethylcellulose via a feeding
needle, except for the 5 non-immunized mice. These 5 non-
infected and non-immunized mice were used to determine the
baseline value from the cementum-enamel junction (CEJ) to the
alveolar bone crest (ABC) in normal mice. The challenge was
carried out 3 times at two-day intervals. Forty-two days after the
last gavage, the mice were killed. We then repeated the experiment
to confirm reproducibility, and performed statistical analysis using
the pooled data from both experiments.
Measurement of Alveolar Bone Loss
Alveolar bone loss was assessed at defined landmark sites on the
maxillary molars of each mouse as described previously
(Gonzalez et al., 2003). We performed measurements (14 sites) of
each skull from the CEJ to the ABC with a stereomicroscope.
Measurements were made under a dissecting microscope fitted
Figure 1. Induction of P. gingivalis-specific serum IgG and salivary sIgA
antibodies in mice immunized with rgpA DNA vaccine via abdominal
skin by Gene Gun (2.5 g/mouse) and mice immunized nasally with
the rgpA-HVJ envelope vector (20 g/mouse). rgpA DNA vaccine was
injected a total of 7 times as indicated by arrows. (A) Serum IgG titers
of mice against sonicates of P. gingivalis were determined on days 0, 7,
14, 28, 35, 42, and 49 after primary immunization (N = 15). Serial
dilutions were used to measure endpoint titers (> 0.15). Results are
means ± standard deviations of log2 ELISA antibody titers. Variation in
endpoint titers was within a two-fold serial dilution. *p < 0.01, against
naïve mice; **p < 0.01 against Gene Gun-immunized mice by one-way
ANOVA, followed by the Student-Newman-Keuls test. (B) Salivary sIgA
titers against sonicates of P. gingivalis were determined on days 0, 7,
14, 28, 35, 42, and 49 after primary immunization. Serial dilutions
were used to measure endpoint titers (> 0.15). Results are means ±
standard deviations of log2 ELISA antibody titers (N = 15). Variation in
endpoint titer was within a two-fold serial dilution. *p < 0.01 against
naïve mice and Gene Gun-immunized mice by one-way ANOVA,
followed by the Student-Newman-Keuls test.
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with a video image-maker measurement system, MS-803
(MORITEX Co., Tokyo, Japan), standardized to give
measurements in millimeters.
Statistical Analysis
We used a one-way ANOVA followed by a Student-Newman-
Keuls test to make multiple comparisons between the relative
protective effects of the DNA vaccinations against bone loss. The
differences in antibody levels among the groups were also
evaluated with a one-way ANOVA, followed by a Student-
Newman-Keuls test.
RESULTS
Responses of Immunoglobulins to P. gingivalis
Specific IgGs were clearly induced in both groups of BALB/c
mice inoculated with the rgpA DNA vaccine, either by Gene
Gun or intranasally (Fig. 1A). Following immunization, the
responses in both groups reached plateaus on day 42. The titers
of IgGs at day 49 in both immunized groups were elevated (p <
0.01), with the Gene Gun group yielding slightly lower titers
than the intranasal group. The specificities of serum IgGs to
recombinant RgpA domains were confirmed as described
previously (Yonezawa et al., 2001).
Intranasal immunization with rgpA DNA vaccine induced
P. gingivalis-specific sIgA responses in the saliva, with this
response reaching a plateau on day 42 (p < 0.01, Fig. 1B). In
contrast, no sIgA production was observed in the Gene Gun
group.
The specificity of salivary sIgA against each recombinant
RgpA domain is shown in Fig. 2. It reacted to the catalytic
domains of RgpA, HGRP 44, and HGRP 15-27. The molecular
masses corresponded well with the deduced molecular masses
of the recombinant fusion proteins of each domain with a
histidine-tag of pET32Xa/LIC.
The profiles of the IgG subclasses were the same in both
groups, with the most prevalent subclass being IgG1, followed
by IgG2b (p < 0.01, Fig. 3).
Immunization with rgpA DNA Vaccine Protects against
Alveolar Bone Loss Incurred by Infection with P. gingivalis.
The level of alveolar bone loss was assessed at 42 days after
challenge with P. gingivalis ATCC33277. The infected mice
showed significantly greater maxillary molar alveolar bone loss
than did the uninfected control mice (p < 0.01, Fig. 4). Both the
Gene Gun group and the intranasal group were protected from
alveolar bone loss (p < 0.01), although the magnitude of
protection was greater in the latter (p < 0.01).
DISCUSSION
Gingipain is a major pathogen of P. gingivalis (Potempa et al.,
2003). We found that both serum IgG and sIgA production was
induced in mice intranasally immunized with rgpA DNA
vaccine by an HVJ envelope vector; in contrast, immunization
via the abdominal skin by Gene Gun induced serum IgG alone.
These results suggest that intranasal administration of DNA
vaccine by an HVJ envelope vector can induce a stronger
response in the mucosal immune system. We found that the
levels of induced IgG against RgpA were almost the same in
both groups. These results indicate that intranasal rgpA DNA
vaccine immunization is a more effective procedure for
inducing serum and salivary antibody responses in the absence
of any adjuvant. Kawabata et al. (1999) demonstrated that
injection of fimbriae DNA vaccine into salivary glands induced
salivary IgA and serum IgG. In our results, the level of salivary
Figure 2. Specificity of salivary sIgA against RgpA domains.
Recombinant catalytic domain of RgpA (RgpA Cat, lane 1), 44-kDa
adhesion hemagglutinin domain (HGRP 44, lane 2), and 15-, 17-, and
27-kDa hemagglutinin domains (HGRP 15-27, lane 3) with histidine
tags were separated by SDS-PAGE and transferred to PVDF membrane.
Blotted membrane was blocked with phosphate-buffered saline
containing 3% bovine serum albumin, reacted with peroxidase-
conjugated anti-mouse IgA and developed. Blotted lanes 1, 2, and 3
were probed with saliva from mice immunized nasally with rgpA-HVJ
envelope vector.
Figure 3. P. gingivalis-specific IgG subclass responses against sonicates
of P. gingivalis. Immunization groups of BALB/c mice immunized with
rgpA DNA vaccine via abdominal skin by Gene Gun (2.5 g/mouse)
or immunized nasally with rgpA-HVJ envelope vector (20 g/mouse).
IgG subclass responses were assessed on day 49. Results are means ±
standard deviations of log2 ELISA antibody titers (N = 15). Variation in
endpoint titers was within a two-fold serial dilution. One-way ANOVA
for repeated measurements was used for inter-group comparisons. The
Student-Newman-Keuls test was used for multiple comparisons.
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IgA was almost the same as that reported in their data;
however, the serum IgG titer was lower. It is possible that this
variation in IgG titers was a result of the different
immunization routes used.
Analysis of each IgG subclass level against P. gingivalis
revealed that immunization with rgpA DNA vaccine via
either the abdominal or the intranasal route strongly induced
production of IgG1 and IgG2b. This DNA vaccine offers the
advantage of inducing both humoral and cell-mediated
immune responses. Our results suggest that immunization
with rgpA DNA vaccine preferentially induced antibody via
Th2-type responses. Another group has also reported a
protective effect resulting from serum IgG response to P.
gingivalis (Gibson et al., 2004). Analysis of these data, taken
together, indicates that the induction of antibody via Th2-
type response plays an important role in protecting against
infection by P. gingivalis.
The Th1-type response has been associated with
destruction of periodontal tissue and bone resorption (Takeichi
et al., 2000; Taubman and Kawai, 2001). In an earlier study,
we found that rgpA DNA vaccine induced a reduction in Th1-
type cytokines such as IFN-, and a protective effect in mice
challenged with a lethal dose of P. gingivalis (Yonezawa et al.,
2005). It is possible that the protection afforded by vaccination
with the rgpA DNA vaccine resulted from a reduction in the
Th1-type response. However, the Th1-type reaction plays an
important role in protection against acute infection (Spellberg
and Edwards, 2001). To clarify the relationship between
reduction in Th1-type response and protective response to
vaccination, further analysis is required to investigate the
Th1/Th2 balance in vaccinated mice during the inflammation
process.
Numerous clinical studies in patients with chronic
periodontitis have demonstrated high antibody levels against P.
gingivalis in serum and gingival crevicular fluid (Tew et al.,
1985; Ebersole et al., 1986; Inagaki et al., 2003). However, few
reports have investigated the protective effects of
immunoresponses against periodontal disease in humans. Booth
et al. (1996) found that passive immunization with monoclonal
antibody against P. gingivalis inhibited recolonization. We
previously reported that rgpA DNA vaccine induced a protective
effect against P. gingivalis infection in mice (Yonezawa et al.,
2001). Another study (Genco et al., 1998) showed that a peptide
domain on R gingipain had a protective effect against P.
gingivalis infection in mice. Mice immunized with RgpA
polypeptides were protected from P. gingivalis-elicited oral
bone loss, with this antigen also eliciting a potent IgG response
(Gibson et al., 2001). In addition, IgG against purified RgpA
also showed a protective effect, enhancing PMN-mediated
bacterial killing of P. gingivalis strains (Nakagawa et al., 2001).
When these findings are considered together with the present
results, it seems clear that IgG can exert a preventive effect
against components of P. gingivalis.
Intranasally immunized mice were better protected against
bone loss than those immunized with the Gene Gun, suggesting
that sIgA offers a protective advantage over high IgG antibody
levels alone. Specific sIgA against Streptococcus mutans has a
protective effect against colonization by the pathogens in the
oral cavity (Saito et al., 2001). It is possible that sIgA reduces
colonization by P. gingivalis. However, in this study, it was not
possible to evaluate the inhibition of oral colonization, since P.
gingivalis is not a resident of the oral cavity in the mouse;
furthermore, exposure to such high numbers of this micro-
organism here may have induced bone loss. Such factors must
be taken into account in evaluation of the reduction of
colonization. Therefore, further study is required in a suitable
animal model to clarify the effect of sIgA.
The results of this study suggest that intranasal
immunization with an rgpA DNA vaccine offers strong
potential in the prevention of periodontal disease. This research
offers a new approach to the clinical prevention of periodontal
disease using a combination of rgpA DNA vaccine and the HVJ
envelope vector system.
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Figure 4. Levels of alveolar bone loss elicited following P. gingivalis
oral challenge. BALB/c mice immunized with rgpA DNA vaccine via
abdominal skin by Gene Gun (2.5 g/mouse), mice immunized
nasally with rgpA-HVJ envelope vector (20 g/mouse); control group
consisted of age-matched, non-vaccinated mice and pVAX1
immunized mice orally challenged with P. gingivalis ATCC 33277
(Pg). At 42 days after oral challenge, all mice were killed. Linear
measurements (n = 14 sites) were obtained from the mean of the
maxillary molars in each mouse, and pooled linear measurements (in
millimeters) were calculated for each group (N = 20 for non-infected
naïve mice, P. gingivalis-infected naïve mice, and P. gingivalis-
infected HVJ envelope vector-immunized mice; N = 15 for P.
gingivalis-infected Gene Gun-immunized mice; N = 15 for pVAX1
immunized with HVJ envelope vector). Data are shown as mean ±
standard deviation. One-way ANOVA for repeated measurements
was used for inter-group comparisons. The Student-Newman-Keuls
test was used for multiple comparisons (*p < 0.01).  CEJ = cemento-
enamel junction, ABC = alveolar bone crest. 
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